UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Antibiotics (Basel), 2023-04, Vol.12 (4), p.702

2023

Volltextzugriff (PDF)

Current Insights into Diagnosing and Treating Neurotuberculosis in Adults

CNS drugs, 2023-11, Vol.37 (11), p.957-972

2023

Volltextzugriff (PDF)

RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus

Antimicrobial agents and chemotherapy, 2022-01, Vol.66 (1), p.e0150921-e0150921

2022

Volltextzugriff (PDF)

Rifampicin Transport by OATP1B1 Variants

Antimicrobial agents and chemotherapy, 2020-09, Vol.64 (10)

2020

Volltextzugriff (PDF)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Journal of clinical pharmacology, 2022-03, Vol.62 (3), p.385-396

2022

Volltextzugriff (PDF)

Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol

Antimicrobial agents and chemotherapy, 2016-12, Vol.60 (12), p.7105-7114

2016

Volltextzugriff (PDF)

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Preclinical models to optimize treatment of tuberculous meningitis – A systematic review

Tuberculosis (Edinburgh, Scotland), 2020-05, Vol.122, p.101924, Article 101924

2020

Volltextzugriff (PDF)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Clinical infectious diseases, 2018-06, Vol.67 (1), p.34-41

2018

Volltextzugriff (PDF)

Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example

Journal of antimicrobial chemotherapy, 2024-05, Vol.79 (5), p.1187-1190

2024

Volltextzugriff (PDF)

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Journal of antimicrobial chemotherapy, 2024-10, Vol.79 (10), p.2607-2610

2024

Volltextzugriff (PDF)

Development and validation of an UPLC-MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring

Journal of antimicrobial chemotherapy, 2024-04, Vol.79 (4), p.883-890

2024

Volltextzugriff (PDF)

Results of the first international quality control programme for oral targeted oncolytics

British journal of clinical pharmacology, 2024-01, Vol.90 (1), p.336-343

2024

Volltextzugriff (PDF)

Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations

Journal of antimicrobial chemotherapy, 2024-06, Vol.79 (6), p.1346-1352

2024

Volltextzugriff (PDF)

The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box

Annual review of pharmacology and toxicology, 2018-01, Vol.58 (1), p.271-291

2018

Volltextzugriff (PDF)

Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network

Clinical infectious diseases, 2022-09, Vol.75 (4), p.623-629

2022

Volltextzugriff (PDF)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Antimicrobial agents and chemotherapy, 2023-10, Vol.67 (10), p.e0068323-e0068323

2023

Volltextzugriff (PDF)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis

American journal of respiratory and critical care medicine, 2019-05, Vol.199 (9), p.1166-1167

2019

Volltextzugriff (PDF)

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians

Respiration, 2023-02, Vol.102 (2), p.83-100

2023

Volltextzugriff (PDF)

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients

Clinical pharmacology and therapeutics, 2019-03, Vol.105 (3), p.730-737

2019

Volltextzugriff (PDF)

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma

Biomedical chromatography, 2024-08, Vol.38 (10), p.e5986

2024

Volltextzugriff (PDF)

Determination of protein-unbound, active rifampicin in serum by ultrafiltration and Ultra Performance Liquid Chromatography with UV detection. A method suitable for standard and high doses of rifampicin

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017-09, Vol.1063, p.42-49

2017

Volltextzugriff (PDF)

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters

Tuberculosis (Edinburgh, Scotland), 2016-01, Vol.96, p.150-157

2016

Volltextzugriff (PDF)

Protein binding of rifampicin is not saturated when using high-dose rifampicin

Journal of antimicrobial chemotherapy, 2019-04, Vol.74 (4), p.986-990

2019

Volltextzugriff (PDF)

The potential role of drug transporters and amikacin modifying enzymes in M. avium

Journal of global antimicrobial resistance., 2023-09, Vol.34, p.161-165

2023

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(44)
Buchkapitel
(1)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Pharmacology & Pharmacy
(19)
Tuberculosis
(18)
Microbiology
(16)
Humans
(15)
Infectious Diseases
(15)
Tuberculous Meningitis
(13)
Meningitis
(10)
Pharmacokinetics
(9)
Hiv
(7)
Writing
(7)
Antitubercular Agents - Therapeutic Use
(5)
Brain Research
(5)
Immunology
(5)
Medicine
(5)
Mortality
(5)
Moxifloxacin
(5)
Pharmacology
(5)
Respiratory System
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Current Insights into Diagnosing and Treating Neurotuberculosis in Adults

RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus

Rifampicin Transport by OATP1B1 Variants

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model

Preclinical models to optimize treatment of tuberculous meningitis – A systematic review

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Development and validation of an UPLC-MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring

Results of the first international quality control programme for oral targeted oncolytics

Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations

The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box

Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma

Determination of protein-unbound, active rifampicin in serum by ultrafiltration and Ultra Performance Liquid Chromatography with UV detection. A method suitable for standard and high doses of rifampicin

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters

Protein binding of rifampicin is not saturated when using high-dose rifampicin

The potential role of drug transporters and amikacin modifying enzymes in M. avium

Suchergebnisse filtern